Type 2 Diabetes

Intestinal bacteria levels may be a good marker for determining risk of type 2 diabetes and obesity.

The brains of hyperglycemic patients with Type 1 diabetes produce elevated levels of the neurotransmitter glutamate, which may increase their risk of depression.

Treatment for 12 weeks with empagliflozin led to significant reductions in HbA1c levels and blood pressure compared to placebo.

Posters at ADA 2014 showcased growing popularity of the incretin therapies and SGLT2 inhibitors. Most fascinating to this diabetologist blogger was use of insulin and a GLP-1 RA in a fixed-combination product.

Among women, financial security determines the quality of adjustment to a diabetes diagnosis.

Phase III trial shows that transplanted purified human pancreatic islets safely restored sustained near-normoglycemia and provided protection from severe hypoglycemia in patients with long-standing type 1 diabetes and iatrogenic hypoglycemia.

Researchers find that the ratio of total cholesterol to HDL is a significant predictor for CVD in type 1 diabetes patients who are not using lipid-lowering drugs, and that the ratio of total cholesterol to HDL is a more reliable marker for risk when considering primary prevention.

Researchers have identified a previously unrecognized mechanism for SGLT2 inhibitors in the regulation of glucagon and gluconeogenic gene expression.

Patients with type 1 diabetes who had more depressive symptoms measured at baseline and over time appear to be at an increased risk of mortality, even after allowing for likely mediators.

Designated "meaningful users" of electronic health record systems do not deliver improved care for common chronic diseases.

Although clinicians are increasingly forced to face the 3-headed monster of comorbid diabetes, sleep disturbance, and pain, the healthcare community is only beginning to understand how the conditions overlap.

The latest version of this wearable, automated device can improve glycemia without increasing hypoglycemia. It can handle a wide range of dosing requirements.

Insulin resistance in obese persons at risk for diabetes may be improved with resveratrol used as a dietary supplement, but don’t expect health benefits from resveratrol in red wine.

A genetic variant involved in regulating food intake may play a role in how body mass index affects patients’ susceptibility to diabetes. Reducing total energy intake might help prevent obesity.

By blocking a key pain receptor in mice models, a team of researchers has discovered a potential new method for treating obesity and diabetes.

Patients with type 2 diabetes and inadequate glycemic control treated with dapagliflozin plus metformin and sulfonylurea experienced sustained improvements in HbA1c, fasting plasma glucose, weight loss, and systolic blood pressure over 52 weeks.

Patients between the ages of 55 and 80 with type 2 diabetes treated with canagliflozin for more than 100 weeks experienced significant reductions in HbA1C, fasting plasma glucose, bodyweight, and systolic blood pressure.

Study results show long-term treatment with empagliflozin was well tolerated and associated with reductions in HbA1c, bodyweight, and systolic blood pressure compared with placebo and sitagliptin.

The endocrinologist, the primary care physician, the nurse practitioner: who will do what in the coming days of diabetes care? Just one of the debates going on at the ADA conference.

Here's why incretins are catching on . . . and a strategy that treats not just the whole patient but the whole problem. Live from the ADA convention, highlights here.

Correcting Vitamin D deficiency in susceptible diabetes patients could have considerable metabolic benefit.

To decrease the rates of obesity and type 2 diabetes mellitus (T2DM), a recent study has recommended a ban on sugar-sweetened drinks among food stamp recipients and endorsed an incentive program to encourage healthier eating habits.

Study results presented at ADA 2014 show combination treatment with metformin plus linagliptin delivered consistent HbA1c reductions across different subgroups of patients newly diagnosed with type 2 diabetes, with decreased risk of hypoglycemia.

In response to the growing prevalence of gestational diabetes mellitus and its associated morbidities, much attention has been paid to the use of appropriate screening methodologies for the metabolic disorder.

Study results show that an alternative to currently-marketed injectable agents retains the efficacy of GLP-1 mimetics, while reducing gastrointestinal adverse events and providing the convenience of oral dosing.

Results from the largest population-based, case-control study on the link between incretin therapy and pancreatitis conducted to date indicate that treatment with this class of medications does not confer increased risk of developing pancreatitis.

Combination treatment with insulin degludec and liraglutide was associated with long-term reductions in HbA1c, reduced hypoglycemia risk, and fewer gastrointestinal side effects compared to treatment with the individual medications alone in patients with diabetes.

Patients treated with a new, more concentrated insulin glargine formulation experienced similar glycemic control with fewer nocturnal and daytime hypoglycemic events compared with patients treated with the current formulation of the product.

Study results presented at ADA 2014 show Eli Lilly's investigational long-acting basal insulin analog to have similar clinical efficacy in reducing HbA1c levels as a currently approved injectable insulin glargine product, with a comparable side effect profile.

An A1C goal less stringent than 7% may be appropriate for some patients. In what patients might you make the goal 8%?